Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.
Metastatic Colorectal Cancer
DRUG: C225+CPT-11
Objective Response Rate, defined as complete remission rates and partial remission rates after treatment., Up to 2-4 months
Progress-free Survival(PFS), defined as the period from the date of receiving treatment to disease progress caused by any reason., Up to 2-4 months|Overall Survival(OS), defined as the period from the date of receiving treatment to death caused by any reason., Up to 12 months|Adverse events(AE) and severe adverse events(SAE), defined as the incidence and severity of adverse events related to chemotherapy, Up to 6 months
After first-line treatment of FOLFOX/FOLFIRI/FOLFOXIRI plus Cetuximab failure and defined as RAS/BRAF wild-type by molecular detection of cycle tumor DNA, the patients will be treated with Cetuximab and Irinotecan as a second-line or third-line treatment.